サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784014

肺炎球菌ワクチンの世界市場

Pneumococcal Vaccines

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
肺炎球菌ワクチンの世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺炎球菌ワクチンの世界市場は2030年までに113億米ドルに達する見込み

2024年に83億米ドルと推定される肺炎球菌ワクチンの世界市場は、2024～2030年の分析期間においてCAGR 5.3%で成長し、2030年には113億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである肺炎球菌結合型ワクチンは、CAGR6.2%を記録し、分析期間終了時には74億米ドルに達すると予測されます。肺炎球菌多糖体ワクチン分野の成長率は、分析期間中CAGR 3.6%と推定されます。

米国市場は23億米ドル、中国はCAGR8.5%で成長すると予測

米国の肺炎球菌ワクチン市場は、2024年には23億米ドルになると推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.5%で推移し、2030年には市場規模が23億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.3％と予測されています。欧州では、ドイツがCAGR約3.4%で成長すると予測されています。

肺炎球菌ワクチンの世界市場- 主要動向と促進要因のまとめ

なぜ肺炎球菌ワクチンは公衆衛生にとって重要なのか？

肺炎球菌ワクチン肺炎球菌ワクチンは、肺炎、髄膜炎、敗血症などの重篤な疾患の原因菌である肺炎球菌による感染症の予防に不可欠です。これらの感染症は、特に乳幼児、幼児、高齢者、免疫不全患者に重大な健康リスクをもたらします。肺炎球菌ワクチンの普及により、肺炎球菌に関連する死亡率や罹患率は世界中で大幅に減少し、世界の予防接種プログラムにおける重要性が高まっています。

世界保健機関（WHO）や疾病対策予防センター（CDC）を含む各国政府やヘルスケア機関は、脆弱な人々を守るために肺炎球菌ワクチンの定期接種を強く提唱しています。高所得国や発展途上国の国家予防接種プログラムは、肺炎球菌結合型ワクチン（PCV）や肺炎球菌多糖体ワクチン（PPSV）の普及を加速させ、感染率を大幅に低下させています。さらに、COVID-19の大流行により呼吸器感染症に対する意識が高まり、COVID-19患者の細菌性肺炎による合併症を減らすための広範な公衆衛生イニシアチブの一環として、肺炎球菌ワクチン接種の需要が高まりました。

ワクチン開発における技術革新は市場をどのように変革しているか？

肺炎球菌ワクチン市場は、バイオテクノロジー、ワクチン製剤、予防接種戦略の進歩により急速に発展しています。最も重要な技術革新の一つは、より広い血清型をカバーする次世代肺炎球菌結合型ワクチン（PCV）の開発です。ファイザー、メルク、グラクソ・スミスクライン（GSK）などの大手ワクチンメーカーは、拡大した肺炎球菌株に対する防御を提供する多価PCVを発表し、抗生物質耐性やワクチン非耐性の血清型の出現という課題に対処しています。

例えば、ファイザーのPREVNAR 20とメルクのVAXNEUVANCE（PCV15）は、重症感染症の原因となる肺炎球菌株に対する免疫強化のために設計された次世代ワクチンです。これらのワクチンは、PREVNAR 13やPCV10のような、より少ない血清型に対する防御を提供する旧来の製剤と比べ、大きな進歩を遂げています。さらに、多様な肺炎球菌株に対してより広範で持続性のある免疫を提供することを目的とした、タンパク質をベースとした調査も活発化しています。

肺炎球菌ワクチン研究におけるmRNAワクチン技術の統合も、市場を大きく変える発展です。mRNAワクチンCOVID-19の成功に触発され、各社は開発期間の短縮、有効性の向上、新たな血清型に対する適応性を提供できるmRNAをベースとしたワクチンの研究を進めています。このような技術革新は、特に疾病負担の大きい地域における肺炎球菌感染症予防に革命をもたらす可能性を秘めています。

なぜ世界的に肺炎球菌ワクチン接種の需要が増加しているのか？

予防接種プログラムの拡大、人口の高齢化、呼吸器感染症に対する意識の高まりにより、肺炎球菌ワクチンに対する需要は世界的に高まっています。アフリカ、南アジア、ラテンアメリカなど、乳幼児死亡率が高く、肺炎球菌感染症の負担が大きい国々では、Gavi、Vaccine Alliance、Global Pneumococcal Vaccination Initiative（世界肺炎球菌ワクチン接種イニシアティブ）などの組織とのパートナーシップを通じて、ワクチン接種の取り組みを拡大しています。これらのイニシアチブは、低所得地域におけるワクチン・アクセスを改善することを目的としており、市場拡大を大きく後押ししています。

世界人口の高齢化は、肺炎球菌ワクチン接種の需要を促進するもう一つの重要な要因です。高齢者、特に糖尿病、慢性閉塞性肺疾患（COPD）、心血管疾患などの基礎疾患を持つ高齢者は、肺炎球菌感染症のリスクが高まっています。その結果、多くの国で成人用肺炎球菌ワクチン接種プログラムが導入され、小児期以外の予防接種の普及が促されています。抗菌薬耐性肺炎球菌（AMR）の増加により、予防ワクチン接種の必要性がさらに強調されています。薬剤耐性肺炎球菌は治療の選択肢を制限するため、ワクチン接種が最も効果的な防御策となるからです。

さらに、パンデミック後に呼吸器系の健康が注目されたことで、肺炎球菌ワクチンの接種が加速しました。現在、多くの公衆衛生機関は、高リスク集団に対してインフルエンザやCOVID-19ブースターに加え、肺炎球菌ワクチン接種を推奨しており、成人の定期予防接種プログラムに組み込まれています。製薬業界による投与スケジュールの簡素化や単回投与混合ワクチン（肺炎球菌ワクチンとインフルエンザやRSVワクチンとの組み合わせなど）の開発努力は、特に高齢者や免疫不全患者における摂取をさらに促進すると予想されます。

肺炎球菌ワクチン市場の成長を促進する要因は？

肺炎球菌ワクチン市場の成長は、技術の進歩、世界の予防接種率の向上、ヘルスケア投資の増加など、いくつかの要因によって牽引されています。主な原動力のひとつは、政府の政策や国際的な資金援助イニシアティブに支えられた小児・成人ワクチン接種プログラムの拡大です。各国は定期的な予防接種スケジュールに肺炎球菌ワクチンを組み込んでおり、市場の広範な成長に寄与しています。

もう一つの主要要因は、医薬品の技術革新と競合製品開発です。ワクチンメーカーは、進化する肺炎球菌株に対してより広範な防御を提供するため、製剤の改良を続けています。多価PCVや混合ワクチンの発売により、免疫の持続期間が長くなり、ブースター用量の必要性が減少するため、市場の将来が形成されると予想されます。さらに、コールドチェーン・インフラやワクチン流通ネットワークへの投資により、遠隔地や十分なサービスを受けていない地域でのアクセスが改善されつつあります。

新興経済諸国における肺炎球菌性疾患の負担増も需要を促進しています。インド、中国、ブラジルなどの国では、政府が公衆衛生戦略の一環として肺炎球菌ワクチン接種を優先する傾向が強まっており、普及率の上昇につながっています。さらに、企業との提携や官民協力によってワクチン費用が削減され、低所得者層でも予防接種を受けやすくなっています。

旅行や医療ツーリズムの成長も市場に影響を与える要因の一つです。多くの旅行者、特に肺炎球菌感染症の流行が高い地域を訪れる旅行者が予防ワクチン接種を選択し、先進国と発展途上国の両方で需要が増加しています。

ワクチン技術における継続的な技術革新、肺炎球菌感染症予防に対する意識の高まり、政府と民間セクターの強力な支援により、肺炎球菌ワクチン市場は着実に拡大する態勢を整えています。世界のヘルスケアの優先順位が予防医療と予防接種にシフトし続ける中、肺炎球菌ワクチンは今後も世界の感染症予防の要であり続けるでしょう。

セグメント

ワクチンタイプ（肺炎球菌結合型ワクチン,肺炎球菌多糖体ワクチン）;製品タイプ（Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil,その他製品タイプ）

調査対象企業の例

  • AIM Vaccine Co., Ltd.
  • AstraZeneca
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Vaxcyte, Inc.
  • Walvax Biotechnology Co., Ltd.

AIインテグレイションズ

私たちは、検証された専門家のコンテンツとAIツールで市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32604

Global Pneumococcal Vaccines Market to Reach US$11.3 Billion by 2030

The global market for Pneumococcal Vaccines estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.3 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Pneumococcal Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Pneumococcal Polysaccharide Vaccine segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.5% CAGR

The Pneumococcal Vaccines market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Pneumococcal Vaccine Market - Key Trends & Drivers Summarized

Why Is the Pneumococcal Vaccine Critical for Public Health?

Pneumococcal vaccines are essential in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for serious diseases such as pneumonia, meningitis, and sepsis. These infections pose a significant health risk, particularly to infants, young children, elderly individuals, and immunocompromised patients. The widespread adoption of pneumococcal vaccines has led to a substantial reduction in pneumococcal-related mortality and morbidity worldwide, reinforcing their importance in global immunization programs.

Governments and healthcare organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), strongly advocate for routine pneumococcal vaccination to protect vulnerable populations. National immunization programs in high-income and developing countries have accelerated the uptake of pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), significantly lowering infection rates. Additionally, the COVID-19 pandemic heightened awareness of respiratory infections, leading to increased demand for pneumococcal vaccination as part of broader public health initiatives to reduce complications from bacterial pneumonia in COVID-19 patients.

How Are Innovations in Vaccine Development Transforming the Market?

The pneumococcal vaccine market has evolved rapidly due to advancements in biotechnology, vaccine formulations, and immunization strategies. One of the most significant innovations is the development of next-generation pneumococcal conjugate vaccines (PCVs) with broader serotype coverage. Leading vaccine manufacturers, including Pfizer, Merck, and GlaxoSmithKline (GSK), have introduced multi-valent PCVs that offer protection against an expanded range of pneumococcal strains, addressing the challenge of emerging antibiotic-resistant and non-vaccine serotypes.

For instance, Pfizer’s PREVNAR 20 and Merck’s VAXNEUVANCE (PCV15) are next-generation vaccines designed to provide enhanced immunity against pneumococcal strains responsible for severe infections. These vaccines represent a major advancement over older formulations such as PREVNAR 13 and PCV10, which offered protection against fewer serotypes. Additionally, research into protein-based pneumococcal vaccines is gaining momentum, aiming to provide broader and more durable immunity against diverse pneumococcal strains.

Another transformative development in the market is the integration of mRNA vaccine technology in pneumococcal vaccine research. Inspired by the success of mRNA COVID-19 vaccines, companies are exploring mRNA-based pneumococcal vaccines that could offer quicker development timelines, improved efficacy, and adaptability against emerging serotypes. Such innovations have the potential to revolutionize pneumococcal disease prevention, especially in regions with high disease burdens.

Why Is Global Demand for Pneumococcal Vaccination Increasing?

The demand for pneumococcal vaccines is rising globally due to expanding immunization programs, aging populations, and increased awareness of respiratory infections. Countries with high infant mortality rates and a high burden of pneumococcal disease, such as those in Africa, South Asia, and Latin America, are scaling up vaccination efforts through partnerships with organizations like Gavi, the Vaccine Alliance, and the Global Pneumococcal Vaccination Initiative. These initiatives aim to improve vaccine access in low-income regions, significantly driving market expansion.

The aging global population is another critical factor fueling demand for pneumococcal vaccination. Older adults, especially those with underlying health conditions such as diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases, face a heightened risk of pneumococcal infections. As a result, many countries have introduced adult pneumococcal vaccination programs, encouraging widespread immunization beyond childhood schedules. The rising prevalence of antimicrobial resistance (AMR) has further emphasized the need for preventive vaccination, as drug-resistant pneumococcal strains limit treatment options, making vaccination the most effective defense.

Additionally, the post-pandemic focus on respiratory health has accelerated pneumococcal vaccine uptake. Many public health agencies now recommend pneumococcal vaccination alongside flu and COVID-19 boosters for high-risk populations, integrating it into routine adult immunization programs. The pharmaceutical industry’s efforts to simplify dosing schedules and develop single-dose combination vaccines (e.g., pneumococcal vaccines combined with influenza or RSV vaccines) are expected to further drive uptake, particularly among elderly patients and immunocompromised individuals.

What Factors Are Driving the Growth of the Pneumococcal Vaccine Market?

The growth in the pneumococcal vaccine market is driven by several factors, including technological advancements, increasing global immunization coverage, and rising healthcare investments. One of the primary drivers is the expansion of pediatric and adult vaccination programs, supported by government policies and international funding initiatives. Countries are incorporating pneumococcal vaccines into routine immunization schedules, contributing to widespread market growth.

Another key factor is pharmaceutical innovation and competitive product development. Vaccine manufacturers are continuously enhancing their formulations to provide broader protection against evolving pneumococcal strains. The launch of multi-valent PCVs and combination vaccines is expected to shape the future of the market, offering longer-lasting immunity and reduced booster dose requirements. Additionally, investments in cold chain infrastructure and vaccine distribution networks are improving access to pneumococcal vaccines in remote and underserved regions.

The rising burden of pneumococcal diseases in emerging economies is also driving demand. Governments in countries like India, China, and Brazil are increasingly prioritizing pneumococcal vaccination as part of their public health strategies, leading to higher adoption rates. Additionally, corporate partnerships and public-private collaborations are helping reduce vaccine costs, making immunization more affordable for lower-income populations.

The growth of travel and medical tourism is another factor influencing the market. Many travelers, particularly those visiting regions with high pneumococcal disease prevalence, are opting for preventive vaccination, increasing demand in both developed and developing countries.

With ongoing innovations in vaccine technology, increasing awareness of pneumococcal disease prevention, and strong government and private sector support, the pneumococcal vaccine market is poised for steady expansion. As global healthcare priorities continue to shift toward preventive care and immunization, pneumococcal vaccines will remain a cornerstone of infectious disease prevention worldwide.

SCOPE OF STUDY:

The report analyzes the Pneumococcal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine); Product Type (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Product Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AIM Vaccine Co., Ltd.
  • AstraZeneca
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Vaxcyte, Inc.
  • Walvax Biotechnology Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Pneumococcal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Pneumonia and Invasive Pneumococcal Disease Drives Demand for Widespread Immunization
    • Expansion of National Immunization Programs in Emerging Markets Strengthens Routine Pediatric Vaccine Uptake
    • Aging Population and Increased Comorbidity Risk Spur Adult and Geriatric Pneumococcal Vaccination Campaigns
    • Introduction of Conjugate Vaccines With Broader Serotype Coverage Enhances Preventive Effectiveness and Adoption
    • WHO and GAVI-Led Global Health Initiatives Expand Access to Pneumococcal Vaccines in Low-Income Countries
    • Pharmaceutical Innovation in Multivalent and Next-Gen Pneumococcal Vaccines Drives Market Differentiation
    • Combination Vaccines With DTP or Influenza Components Simplify Immunization Schedules and Improve Adherence
    • Rising Antimicrobial Resistance Concerns Amplify Preventive Role of Vaccines in Reducing Bacterial Infections
    • Increased Investment in Cold Chain Infrastructure Enhances Vaccine Storage and Distribution in Remote Areas
    • Private Sector Expansion of Adult Vaccine Clinics and Retail Pharmacies Boosts Urban Accessibility
    • Regulatory Acceleration and Fast-Track Approvals Speed Up Introduction of New Vaccine Candidates
    • Serotype Replacement and Regional Epidemiology Trends Influence Market Dynamics and R&D Priorities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pneumococcal Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pneumococcal Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pneumococcal Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pneumococcal Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pneumococcal Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pneumococcal Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Pneumococcal Polysaccharide Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prevnar 13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prevnar 13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Prevnar 13 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Synflorix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Synflorix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Synflorix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pneumovax 23 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pneumovax 23 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pneumovax 23 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaxneuvance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vaxneuvance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Vaxneuvance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pneumosil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pneumosil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pneumosil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • CHINA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pneumococcal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pneumococcal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • INDIA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pneumococcal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pneumococcal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030

IV. COMPETITION